Virulence	Virulence	NNP	O
is	be	VBZ	O
labelled	label	VBN	O
as	as	IN	O
the	the	DT	O
ability	ability	NN	O
of	of	IN	O
a	a	DT	O
microorganism	microorganism	NN	O
to	to	TO	O
infect	infect	VB	O
the	the	DT	O
host	host	NN	O
and	and	CC	O
cause	cause	VB	O
a	a	DT	O
disease	disease	NN	O
.	.	.	O

Virulence	virulence	NN	O
factors	factor	NNS	O
are	be	VBP	O
molecules	molecule	NNS	O
that	that	WDT	O
assist	assist	VBP	O
the	the	DT	O
pathogen	pathogen	NN	O
to	to	TO	O
colonise	colonise	VB	O
the	the	DT	O
host	host	NN	O
at	at	IN	O
the	the	DT	O
cellular	cellular	JJ	O
level	level	NN	B
.	.	.	O

These	these	DT	O
factors	factor	NNS	O
can	can	MD	O
be	be	VB	O
either	either	CC	O
secretory	secretory	RB	O
,	,	,	O
membrane	membrane	NN	O
associated	associate	VBD	O
or	or	CC	O
cytosolic	cytosolic	JJ	O
and	and	CC	O
facilitate	facilitate	VB	O
the	the	DT	O
microorganism	microorganism	NN	O
metabolic	metabolic	NN	O
,	,	,	O
physiological	physiological	JJ	O
,	,	,	O
and	and	CC	O
morphological	morphological	JJ	O
adaption	adaption	NN	O
in	in	IN	O
the	the	DT	O
host	host	NN	B
,	,	,	B
.	.	.	O

Virulence	virulence	NN	O
factors	factor	NNS	O
are	be	VBP	O
deeply	deeply	RB	O
implicated	implicate	VBN	O
in	in	IN	O
the	the	DT	O
onset	onset	NN	O
of	of	IN	O
pharmacological	pharmacological	JJ	O
resistance	resistance	NN	O
to	to	IN	O
anti	anti	NNS	O
-	-	NNS	O
infectives	infective	NNS	O
.	.	.	O

Preventing	prevent	VBG	O
the	the	DT	O
implementation	implementation	NN	O
of	of	IN	O
these	these	DT	O
processes	process	NNS	O
is	be	VBZ	O
a	a	DT	O
strategy	strategy	NN	O
deemed	deem	VBN	O
successful	successful	JJ	O
to	to	IN	O
date	date	NN	O
to	to	TO	O
overcome	overcome	VB	O
drug	drug	NN	O
-	-	HYPH	O
resistance	resistance	NN	B
.	.	.	O

Targeting	target	VBG	O
virulence	virulence	NN	O
factors	factor	NNS	O
might	may	MD	O
indeed	indeed	RB	O
reduce	reduce	VB	O
,	,	,	O
eliminate	eliminate	VB	O
,	,	,	O
and/or	and/or	CC	O
reverse	reverse	VB	O
the	the	DT	O
evolutionary	evolutionary	JJ	O
selective	selective	JJ	O
pressures	pressure	NNS	O
that	that	WDT	O
induce	induce	VBP	O
the	the	DT	O
pathogen	pathogen	NN	O
to	to	TO	O
develop	develop	VB	O
resistance	resistance	NN	O
,	,	,	O
which	which	WDT	O
represents	represent	VBZ	O
a	a	DT	O
main	main	JJ	O
threat	threat	NN	O
to	to	IN	O
human	human	JJ	O
health	health	NN	O
nowadays	nowadays	RB	O
.	.	.	O

The	the	DT	O
metalloenzymes	metalloenzymes	NNP	O
carbonic	carbonic	NNP	O
anhydrases	anhydrase	NNS	O
CAs	CAs	NNP	O
,	,	,	O
EC	EC	NNP	O
4.2.1.1	4.2.1.1	CD	O
have	have	VBP	O
been	be	VBN	O
shown	show	VBN	O
to	to	TO	O
play	play	VB	O
critical	critical	JJ	O
roles	role	NNS	O
in	in	IN	O
the	the	DT	O
virulence	virulence	NN	O
of	of	IN	O
many	many	JJ	O
pathogens	pathogen	NNS	O
among	among	IN	O
which	which	WDT	O
bacteria	bacteria	NNS	O
,	,	,	O
fungi	fungi	NN	O
,	,	,	O
and	and	CC	O
protozoa	protozoa	JJ	B
,	,	,	B
.	.	.	O

CAs	CAs	NNP	O
are	be	VBP	O
a	a	DT	O
superfamily	superfamily	RB	O
of	of	IN	O
phylogenetically	phylogenetically	RB	O
ubiquitous	ubiquitous	JJ	O
metalloenzymes	metalloenzyme	NNS	O
,	,	,	O
present	present	JJ	O
in	in	IN	O
Prokaryotes	Prokaryotes	NNPS	O
and	and	CC	O
Eukaryotes	Eukaryotes	NNP	O
,	,	,	O
classified	classify	VBN	O
in	in	IN	O
seven	seven	CD	O
genetically	genetically	RB	O
unrelated	unrelated	JJ	O
families	family	NNS	O
,	,	,	O
Î±	Î±	NNP	O
,	,	,	O
Î²	î²	NN	O
,	,	,	O
Î³	î³	NN	O
,	,	,	O
Î	Î	NNP	O
´	´	NNP	O
,	,	,	O
Î¶	Î¶	NNP	O
,	,	,	O
Î	Î	NNP	O
·	·	NFP	O
,	,	,	O
and	and	CC	O
Î¸	î¸	VB	B
.	.	.	O

By	by	IN	O
catalysing	catalyse	VBG	O
the	the	DT	O
reversible	reversible	JJ	O
hydration	hydration	NN	O
of	of	IN	O
CO2	CO2	NNP	O
to	to	TO	O
HCO3â	HCO3â	NNP	O
and	and	CC	O
H+	H+	JJR	O
,	,	,	O
these	these	DT	O
enzymes	enzyme	NNS	O
are	be	VBP	O
implicated	implicate	VBN	O
in	in	IN	O
many	many	JJ	O
physiological	physiological	JJ	O
processes	process	NNS	O
which	which	WDT	O
are	be	VBP	O
basic	basic	JJ	O
for	for	IN	O
life	life	NN	B
,	,	,	B
.	.	.	O

In	in	IN	O
microorganisms	microorganism	NNS	O
,	,	,	O
CAs	ca	NNS	O
are	be	VBP	O
involved	involve	VBN	O
in	in	IN	O
photosynthesis	photosynthesis	NN	O
cyanobacteria	cyanobacteria	NNP	O
,	,	,	O
biosynthesis	biosynthesis	NN	O
of	of	IN	O
DNA	DNA	NNP	O
,	,	,	O
amino	amino	JJ	O
acids	acid	NNS	O
and	and	CC	O
fatty	fatty	NN	O
acids	acid	NNS	O
,	,	,	O
and	and	CC	O
proliferation	proliferation	NN	O
,	,	,	O
survival	survival	NN	O
and	and	CC	O
differentiation	differentiation	NN	O
of	of	IN	O
pathogens	pathogen	NNS	O
both	both	DT	O
in	in	IN	O
the	the	DT	O
hosts	host	NNS	O
and	and	CC	O
in	in	IN	O
the	the	DT	O
environmental	environmental	JJ	O
niches	niche	NNS	B
,	,	,	B
.	.	.	O

Compelling	compelling	JJ	O
data	datum	NNS	O
exist	exist	VBP	O
in	in	IN	O
the	the	DT	O
literature	literature	NN	O
,	,	,	O
which	which	WDT	O
strongly	strongly	RB	O
indicate	indicate	VBP	O
that	that	IN	O
interference	interference	NN	O
with	with	IN	O
CA	CA	NNP	O
activity	activity	NN	O
in	in	IN	O
various	various	JJ	O
parasites	parasite	NNS	O
leads	lead	VBZ	O
to	to	IN	O
an	an	DT	O
impairment	impairment	NN	O
of	of	IN	O
their	-PRON-	PRP$	O
growth	growth	NN	O
,	,	,	O
which	which	WDT	O
in	in	IN	O
turn	turn	NN	O
leads	lead	VBZ	O
to	to	IN	O
a	a	DT	O
significant	significant	JJ	O
anti	anti	JJ	O
-	-	JJ	O
infective	infective	JJ	O
effect	effect	NN	B
.	.	.	O

Unlike	unlike	IN	O
mammals	mammal	NNS	O
and	and	CC	O
human	human	NN	O
whose	whose	WP$	O
genome	genome	NN	O
uniquely	uniquely	RB	O
encode	encode	VBP	O
for	for	IN	O
Î±-class	î±-class	NN	O
CAs	ca	VBN	O
,	,	,	O
the	the	DT	O
genome	genome	NN	O
of	of	IN	O
many	many	JJ	O
pathogenic	pathogenic	JJ	O
bacteria	bacteria	NNS	O
e.g.	e.g.	RB	O
Vibrio	Vibrio	NNP	O
cholerae	cholerae	NN	B
,	,	,	O
Francisella	Francisella	NNP	O
tularensis	tularensis	VBP	B
,	,	,	O
Burkholderia	Burkholderia	NNP	O
pseudomalei	pseudomalei	VBP	B
,	,	,	O
the	the	DT	O
Gram	Gram	NNP	O
-	-	HYPH	O
negative	negative	JJ	O
bacteria	bacteria	NNS	O
provoking	provoke	VBG	O
cholera	cholera	NNS	O
,	,	,	O
tularaemia	tularaemia	NN	O
,	,	,	O
and	and	CC	O
melioidosis	melioidosis	NN	O
,	,	,	O
fungi	fungi	NNP	O
e.g.	e.g.	RB	O
Candida	Candida	NNP	O
glabrata	glabrata	VBP	B
,	,	,	O
Cryptococcus	Cryptococcus	NNP	O
neoformans	neoforman	NNS	B
,	,	,	O
or	or	CC	O
Malassezia	malassezia	JJ	O
globosa	globosa	JJ	B
,	,	,	O
respectively	respectively	RB	O
responsible	responsible	JJ	O
of	of	IN	O
candidiasis	candidiasis	NN	O
,	,	,	O
cryptococcosis	cryptococcosis	NN	O
,	,	,	O
and	and	CC	O
dandruff	dandruff	NNS	O
,	,	,	O
and	and	CC	O
protozoa	protozoa	JJ	O
e.g.	e.g.	RB	O
Leismania	Leismania	NNP	O
donovani	donovani	NNP	O
chagasi	chagasi	NNP	O
which	which	WDT	O
provokes	provoke	VBZ	O
leishmaniasis	leishmaniasis	NN	B
encode	encode	VBP	O
for	for	IN	O
Î²-class	î²-class	JJ	O
enzymes	enzyme	NNS	O
.	.	.	O

Actually	actually	RB	O
,	,	,	O
the	the	DT	O
seven	seven	CD	O
different	different	JJ	O
CA	CA	NNP	O
classes	class	NNS	O
do	do	VBP	O
not	not	RB	O
show	show	VB	O
significant	significant	JJ	O
structural	structural	JJ	O
homology	homology	NN	O
with	with	IN	O
each	each	DT	O
other	other	JJ	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
CAs	ca	NNS	O
of	of	IN	O
the	the	DT	O
same	same	JJ	O
class	class	NN	O
but	but	CC	O
belonging	belong	VBG	O
to	to	IN	O
genetically	genetically	RB	O
distant	distant	JJ	O
species	specie	NNS	O
,	,	,	O
show	show	VB	O
differences	difference	NNS	O
at	at	IN	O
the	the	DT	O
level	level	NN	O
of	of	IN	O
their	-PRON-	PRP$	O
catalytic	catalytic	JJ	O
site	site	NN	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
a	a	DT	O
probable	probable	JJ	O
and	and	CC	O
realistic	realistic	JJ	O
possibility	possibility	NN	O
to	to	TO	O
develop	develop	VB	O
selective	selective	JJ	O
CA	CA	NNP	O
inhibitors	inhibitor	NNS	O
exists	exist	VBZ	O
.	.	.	O

Î²-CAs	î²-ca	VBN	O
exist	exist	VBP	O
as	as	IN	O
oligomers	oligomer	NNS	O
formed	form	VBN	O
by	by	IN	O
two	two	CD	O
or	or	CC	O
more	more	JJR	O
identical	identical	JJ	O
subunits	subunit	NNS	O
such	such	JJ	O
as	as	IN	O
dimers	dimer	NNS	O
,	,	,	O
tetramers	tetramer	NNS	O
,	,	,	O
and	and	CC	O
octamers	octamer	NNS	B
.	.	.	O

Sulphonamides	sulphonamide	NNS	O
and	and	CC	O
bioisosteres	bioisostere	NNS	O
are	be	VBP	O
the	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
class	class	NN	O
of	of	IN	O
CA	CA	NNP	O
inhibitors	inhibitor	NNS	O
CAIs	CAIs	NNP	O
and	and	CC	O
have	have	VBP	O
been	be	VBN	O
,	,	,	O
probably	probably	RB	O
exhaustively	exhaustively	RB	O
,	,	,	O
exploited	exploit	VBN	O
to	to	IN	O
date	date	NN	O
in	in	IN	O
the	the	DT	O
design	design	NN	O
of	of	IN	O
inhibitors	inhibitor	NNS	O
against	against	IN	O
almost	almost	RB	O
every	every	DT	O
known	know	VBN	O
CA	CA	NNP	B
.	.	.	O

Nonetheless	nonetheless	RB	O
,	,	,	O
these	these	DT	O
chemotypes	chemotype	NNS	O
commonly	commonly	RB	O
show	show	VBP	O
a	a	DT	O
weak	weak	JJ	O
isoform	isoform	NN	O
-	-	HYPH	O
selectivity	selectivity	NN	O
both	both	CC	O
within	within	IN	O
the	the	DT	O
subset	subset	NN	O
of	of	IN	O
human	human	JJ	O
CAs	ca	NNS	O
and	and	CC	O
between	between	IN	O
isoforms	isoform	NNS	O
from	from	IN	O
distinct	distinct	JJ	O
classes	class	NNS	O
,	,	,	O
such	such	JJ	O
as	as	IN	O
Î±-	Î±-	NNP	O
and	and	CC	O
Î²-	î²-	NN	B
.	.	.	O

As	as	IN	O
a	a	DT	O
result	result	NN	O
,	,	,	O
many	many	JJ	O
other	other	JJ	O
chemotypes	chemotype	NNS	O
phenols	phenol	NNS	B
,	,	,	B
,	,	,	O
mono-	mono-	NN	O
and	and	CC	O
dithiocarbammates	dithiocarbammate	VBZ	B
,	,	,	B
,	,	,	O
boroles	borole	NNS	B
,	,	,	O
carboxylates	carboxylate	NNS	O
,	,	,	B
N	n	CD	O
-	-	HYPH	O
nitrosulfonamides	nitrosulfonamide	NNS	B
,	,	,	B
have	have	VBP	O
been	be	VBN	O
investigated	investigate	VBN	O
as	as	IN	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
Î²-CAs	Î²-CAs	NNP	O
to	to	TO	O
identify	identify	VB	O
selective	selective	JJ	O
modulators	modulator	NNS	O
for	for	IN	O
targeting	target	VBG	O
the	the	DT	O
pathogens	pathogen	NNS	O
encoding	encode	VBG	O
for	for	IN	O
enzymes	enzyme	NNS	O
of	of	IN	O
this	this	DT	O
class	class	NN	O
.	.	.	O

Among	among	IN	O
these	these	DT	O
,	,	,	O
N	n	NN	O
-	-	HYPH	O
nitrosulfonamides	nitrosulfonamide	NNS	O
,	,	,	O
phenols	phenol	NNS	O
,	,	,	O
and	and	CC	O
natural	natural	JJ	O
polyphenols	polyphenol	NNS	O
stood	stand	VBD	O
out	out	RP	O
as	as	IN	O
selective	selective	JJ	O
inhibitors	inhibitor	NNS	O
for	for	IN	O
Î²-class	î²-class	JJ	O
CAs	ca	NNS	O
from	from	IN	O
pathogens	pathogen	NNS	O
over	over	IN	O
human	human	JJ	O
ubiquitous	ubiquitous	JJ	O
CAs	cas	JJ	B
,	,	,	B
,	,	,	B
.	.	.	O

A	a	DT	O
recent	recent	JJ	O
paper	paper	NN	O
by	by	IN	O
us	-PRON-	PRP	O
showed	show	VBD	O
for	for	IN	O
the	the	DT	O
first	first	JJ	O
time	time	NN	O
that	that	WDT	O
phosphonamidates	phosphonamidate	NNS	O
are	be	VBP	O
able	able	JJ	O
to	to	TO	O
inhibit	inhibit	VB	O
human	human	JJ	O
CAs	ca	NNS	O
in	in	IN	O
the	the	DT	O
micromolar	micromolar	JJ	O
range	range	NN	O
acting	act	VBG	O
a	a	DT	O
sulphonamide	sulphonamide	NN	O
biomimetics	biomimetic	NNS	O
additionally	additionally	RB	O
possessing	possess	VBG	O
a	a	DT	O
chiral	chiral	JJ	O
binding	bind	VBG	O
mode	mode	NN	O
Figure	figure	NN	O
1	1	CD	O
)	)	-RRB-	B
.	.	.	O

Up	up	IN	O
to	to	IN	O
now	now	RB	O
,	,	,	O
no	no	DT	O
one	one	NN	O
scheduled	schedule	VBN	O
testing	testing	NN	O
phosphorus	phosphorus	NN	O
based	base	VBN	O
binding	bind	VBG	O
motifs	motif	NNS	O
against	against	IN	O
Î²-class	Î²-class	NNP	O
CAs	CAs	NNP	O
.	.	.	O

Considering	consider	VBG	O
the	the	DT	O
interesting	interesting	JJ	O
results	result	NNS	O
reported	report	VBN	O
earlier	early	RBR	O
against	against	IN	O
these	these	DT	O
enzymes	enzyme	NNS	O
,	,	,	O
here	here	RB	O
we	-PRON-	PRP	O
report	report	VBP	O
an	an	DT	O
inhibition	inhibition	NN	O
study	study	NN	O
with	with	IN	O
benzenephosphonamidates	benzenephosphonamidate	NNS	O
against	against	IN	O
Î²-CAs	Î²-CAs	NNP	O
from	from	IN	O
pathogenic	pathogenic	JJ	O
bacteria	bacteria	NNS	O
,	,	,	O
fungi	fungi	NN	O
,	,	,	O
and	and	CC	O
protozoa	protozoa	RB	O
working	work	VBG	O
out	out	RP	O
their	-PRON-	PRP$	O
structureâactivity	structureâactivity	NN	O
relationship	relationship	NN	O
SAR	SAR	NNP	O
in	in	IN	O
comparison	comparison	NN	O
to	to	TO	O
hCA	hca	VB	O
I	-PRON-	PRP	O
and	and	CC	O
II	II	NNP	O
previously	previously	RB	O
reported	report	VBN	O
inhibition	inhibition	NN	O
.	.	.	O

In	in	IN	O
silico	silico	NNS	O
predicted	predict	VBD	O
binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
A	a	NN	O
phenylphosphonic	phenylphosphonic	NN	O
diamide	diamide	NN	O
2	2	CD	O
,	,	,	O
B	b	NN	O
S)-4	s)-4	NN	O
and	and	CC	O
C	c	NN	O
R)-4	R)-4	VBN	O
to	to	IN	O
hCA	hca	CD	O
II	II	NNP	O
,	,	,	O
as	as	IN	O
repoted	repot	VBN	O
in	in	IN	O
Nocentini	Nocentini	NNP	O
etÂ	etÂ	NNP	O
al	al	NNP	O
.	.	.	O

CYTOWANIEThe	cytowaniethe	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
phenylphosphonic	phenylphosphonic	JJ	O
diamide	diamide	NN	O
2	2	CD	O
and	and	CC	O
alkyl	alkyl	NN	O
phosphonamidates	phosphonamidate	NNS	O
3â10	3â10	CD	O
was	be	VBD	O
reported	report	VBN	O
earlier	early	RBR	O
by	by	IN	O
our	-PRON-	PRP$	O
group	group	NN	B
.	.	.	O

An	an	DT	O
Sx.18Mv	Sx.18Mv	NNP	O
-	-	HYPH	O
R	R	NNP	O
Applied	Applied	NNP	O
Photophysics	Photophysics	NNP	O
Oxford	Oxford	NNP	O
,	,	,	O
UK	UK	NNP	O
stopped	stop	VBD	O
-	-	HYPH	O
flow	flow	NN	O
instrument	instrument	NN	O
has	have	VBZ	O
been	be	VBN	O
used	use	VBN	O
to	to	TO	O
assay	assay	VB	O
the	the	DT	O
catalytic	catalytic	JJ	O
activity	activity	NN	O
of	of	IN	O
various	various	JJ	O
CA	CA	NNP	O
isozymes	isozyme	NNS	O
for	for	IN	O
CO2	CO2	NNP	O
hydration	hydration	NN	O
reaction	reaction	NN	B
.	.	.	O

Phenol	Phenol	NNP	O
red	red	JJ	O
at	at	IN	O
a	a	DT	O
concentration	concentration	NN	O
of	of	IN	O
0.2âmM	0.2âmm	NN	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
indicator	indicator	NN	O
,	,	,	O
working	work	VBG	O
at	at	IN	O
the	the	DT	O
absorbance	absorbance	NN	O
maximum	maximum	NN	O
of	of	IN	O
557ânm	557ânm	CD	O
,	,	,	O
with	with	IN	O
10âmM	10âmm	CD	O
Hepes	Hepes	NNPS	O
pH	pH	NNP	O
7.5	7.5	CD	O
,	,	,	O
for	for	IN	O
Î±-CAs	î±-cas	JJ	O
or	or	CC	O
TRIS	TRIS	NNP	O
pH	pH	NNP	O
8.3	8.3	CD	O
,	,	,	O
for	for	IN	O
Î²-CAs	Î²-CAs	NNP	O
as	as	IN	O
buffers	buffer	NNS	O
,	,	,	O
and	and	CC	O
20âmM	20âmm	CD	O
Na2SO4	Na2SO4	NNP	O
for	for	IN	O
maintaining	maintain	VBG	O
constant	constant	JJ	O
the	the	DT	O
ionic	ionic	JJ	O
strength	strength	NN	O
,	,	,	O
following	follow	VBG	O
the	the	DT	O
initial	initial	JJ	O
rates	rate	NNS	O
of	of	IN	O
the	the	DT	O
CA	CA	NNP	O
-	-	HYPH	O
catalysed	catalyse	VBN	O
CO2	CO2	NNP	O
hydration	hydration	NN	O
reaction	reaction	NN	O
for	for	IN	O
a	a	DT	O
period	period	NN	O
of	of	IN	O
10â100âs	10â100âs	CD	O
.	.	.	O

The	the	DT	O
CO2	CO2	NNP	O
concentrations	concentration	NNS	O
ranged	range	VBD	O
from	from	IN	O
1.7	1.7	CD	O
to	to	TO	O
17âmM	17âmm	CD	O
for	for	IN	O
the	the	DT	O
determination	determination	NN	O
of	of	IN	O
the	the	DT	O
kinetic	kinetic	JJ	O
parameters	parameter	NNS	O
and	and	CC	O
inhibition	inhibition	NN	O
constants	constant	NNS	O
.	.	.	O

For	for	IN	O
each	each	DT	O
inhibitor	inhibitor	NN	O
,	,	,	O
at	at	IN	O
least	least	JJS	O
six	six	CD	O
traces	trace	NNS	O
of	of	IN	O
the	the	DT	O
initial	initial	JJ	O
5â10	5â10	CD	O
%	%	NN	O
of	of	IN	O
the	the	DT	O
reaction	reaction	NN	O
have	have	VBP	O
been	be	VBN	O
used	use	VBN	O
for	for	IN	O
determining	determine	VBG	O
the	the	DT	O
initial	initial	JJ	O
velocity	velocity	NN	O
.	.	.	O

The	the	DT	O
uncatalyzed	uncatalyzed	JJ	O
rates	rate	NNS	O
were	be	VBD	O
determined	determine	VBN	O
in	in	IN	O
the	the	DT	O
same	same	JJ	O
manner	manner	NN	O
and	and	CC	O
subtracted	subtract	VBD	O
from	from	IN	O
the	the	DT	O
total	total	JJ	O
observed	observed	JJ	O
rates	rate	NNS	O
.	.	.	O

Stock	stock	NN	O
solutions	solution	NNS	O
of	of	IN	O
inhibitor	inhibitor	NN	O
0.1âmM	0.1âmm	CD	O
were	be	VBD	O
prepared	prepare	VBN	O
in	in	IN	O
distilledâdeionised	distilledâdeionise	VBN	O
water	water	NN	O
and	and	CC	O
dilutions	dilution	NNS	O
up	up	RB	O
to	to	IN	O
0.01ânM	0.01ânm	NN	O
were	be	VBD	O
done	do	VBN	O
thereafter	thereafter	RB	O
with	with	IN	O
the	the	DT	O
assay	assay	NN	O
buffer	buffer	NN	O
.	.	.	O

Inhibitor	inhibitor	NN	O
and	and	CC	O
enzyme	enzyme	NNS	O
solutions	solution	NNS	O
were	be	VBD	O
preincubated	preincubate	VBN	O
together	together	RB	O
for	for	IN	O
1âh	1âh	CD	O
at	at	IN	O
room	room	NN	O
temperature	temperature	NN	O
prior	prior	RB	O
to	to	IN	O
assay	assay	NNP	O
,	,	,	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
allow	allow	VB	O
for	for	IN	O
the	the	DT	O
formation	formation	NN	O
of	of	IN	O
the	the	DT	O
EâI	EâI	NNP	O
complex	complex	NN	O
.	.	.	O

The	the	DT	O
inhibition	inhibition	NN	O
constants	constant	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
by	by	IN	O
nonlinear	nonlinear	JJ	O
least	least	JJS	O
-	-	HYPH	O
squares	square	NNS	O
methods	method	NNS	O
using	use	VBG	O
PRISM	PRISM	NNP	O
3	3	CD	O
and	and	CC	O
the	the	DT	O
ChengâPrusoff	ChengâPrusoff	NNP	O
equation	equation	NN	O
,	,	,	O
as	as	IN	O
reported	report	VBN	O
earlier	early	RBR	O
,	,	,	O
and	and	CC	O
represent	represent	VB	O
the	the	DT	O
mean	mean	NN	O
from	from	IN	O
at	at	RB	O
least	least	RBS	O
three	three	CD	O
different	different	JJ	O
determinations	determination	NNS	B
,	,	,	B
.	.	.	O

All	all	DT	O
CA	CA	NNP	O
isoforms	isoform	NNS	O
were	be	VBD	O
recombinant	recombinant	JJ	O
ones	one	NNS	O
obtained	obtain	VBN	O
in	in	IN	O
-	-	HYPH	O
house	house	NN	O
as	as	IN	O
reported	report	VBN	O
earlier	early	JJR	B
,	,	,	B
.	.	.	O

A	a	DT	O
straightforward	straightforward	JJ	O
strategy	strategy	NN	O
was	be	VBD	O
used	use	VBN	O
to	to	TO	O
synthesise	synthesise	VB	O
the	the	DT	O
compounds	compound	NNS	O
starting	start	VBG	O
from	from	IN	O
phenylphosphonic	phenylphosphonic	JJ	O
dichloride	dichloride	NN	O
1	1	CD	B
Scheme	scheme	NN	O
1	1	CD	O
.	.	.	O

Phenylphosphonic	phenylphosphonic	JJ	O
diamide	diamide	NN	O
2	2	CD	O
was	be	VBD	O
obtained	obtain	VBN	O
by	by	IN	O
reacting	react	VBG	O
1	1	CD	O
with	with	IN	O
an	an	DT	O
aqueous	aqueous	JJ	O
solution	solution	NN	O
of	of	IN	O
35	35	CD	O
%	%	NN	O
ammonia	ammonia	NN	O
.	.	.	O

Derivative	derivative	JJ	O
2	2	CD	O
was	be	VBD	O
converted	convert	VBN	O
to	to	IN	O
alkyl	alkyl	NN	O
phosphonamidates	phosphonamidate	VBZ	O
3â10	3â10	CD	O
by	by	IN	O
reaction	reaction	NN	O
with	with	IN	O
the	the	DT	O
proper	proper	JJ	O
alcohol	alcohol	NN	O
,	,	,	O
as	as	IN	O
described	describe	VBN	O
in	in	IN	O
the	the	DT	O
literature	literature	NN	B
Scheme	scheme	NN	O
1	1	CD	O
.	.	.	O

Unlike	unlike	IN	O
the	the	DT	O
diamide	diamide	NN	O
derivative	derivative	NN	O
2	2	CD	O
,	,	,	O
all	all	DT	O
alkyl	alkyl	NN	O
phosphonamidates	phosphonamidate	NNS	O
3â10	3â10	CD	O
were	be	VBD	O
obtained	obtain	VBN	O
as	as	IN	O
racemic	racemic	JJ	O
mixtures	mixture	NNS	O
of	of	IN	O
R	R	NNP	O
and	and	CC	O
S	S	NNP	O
optical	optical	JJ	O
isomers	isomer	NNS	O
.	.	.	O

Synthesis	Synthesis	NNP	O
of	of	IN	O
benzenephosphonamidate	benzenephosphonamidate	NN	O
derivatives	derivative	NNS	O
.	.	.	O

Phenylphosphonic	phenylphosphonic	JJ	O
diamide	diamide	NN	O
2	2	CD	O
and	and	CC	O
alkyl	alkyl	NN	O
phosphonamidates	phosphonamidate	NNS	O
3â10	3â10	CD	O
were	be	VBD	O
assayed	assay	VBN	O
as	as	IN	O
inhibitors	inhibitor	NNS	O
of	of	IN	O
a	a	DT	O
panel	panel	NN	O
of	of	IN	O
Î²-class	î²-class	JJ	O
CAs	ca	NNS	O
from	from	IN	O
pathogenic	pathogenic	JJ	O
bacteria	bacteria	NNS	O
,	,	,	O
fungi	fungi	NN	O
,	,	,	O
and	and	CC	O
protozoa	protozoa	NN	O
:	:	:	O
VChÎ²	vchî²	ADD	O
from	from	IN	O
V.	V.	NNP	O
cholerae	cholerae	NNP	O
,	,	,	O
FtuÎ²CA	ftuî²ca	NN	O
from	from	IN	O
F.	F.	NNP	O
tularensis	tularensis	NNP	O
,	,	,	O
BpsCAÎ²	BpsCAÎ²	NNP	O
from	from	IN	O
B.	B.	NNP	O
pseudomalei	pseudomalei	NNP	O
,	,	,	O
Can2	Can2	NNP	O
from	from	IN	O
C.	C.	NNP	O
neoformans	neoformans	NNP	O
,	,	,	O
CgNce	CgNce	NNP	O
from	from	IN	O
C.	C.	NNP	O
glabrata	glabrata	NNP	O
,	,	,	O
MgCA	MgCA	NNP	O
from	from	IN	O
M.	M.	NNP	O
globosa	globosa	NNP	O
,	,	,	O
and	and	CC	O
LdcCA	LdcCA	NNP	O
from	from	IN	O
L.	L.	NNP	O
donovani	donovani	NNP	O
chagasi	chagasi	NNP	O
.	.	.	O

A	a	DT	O
stopped	stop	VBN	O
flow	flow	NN	O
CO2	CO2	NNP	O
hydrase	hydrase	NN	O
assay	assay	NN	O
was	be	VBD	O
used	use	VBN	O
including	include	VBG	O
acetazolamide	acetazolamide	NN	O
AAZ	AAZ	NNP	O
as	as	IN	O
standard	standard	JJ	O
inhibitor	inhibitor	NN	B
.	.	.	O

A	a	DT	O
longer	long	JJR	O
preincubation	preincubation	NN	O
between	between	IN	O
compounds	compound	NNS	O
2â10	2â10	CD	O
and	and	CC	O
the	the	DT	O
enzymes	enzyme	NNS	O
1âh	1âh	CD	O
was	be	VBD	O
necessary	necessary	JJ	O
to	to	TO	O
observe	observe	VB	O
their	-PRON-	PRP$	O
maximum	maximum	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
in	in	IN	O
comparison	comparison	NN	O
to	to	IN	O
the	the	DT	O
15âmin	15âmin	CD	O
incubation	incubation	NN	O
which	which	WDT	O
is	be	VBZ	O
commonly	commonly	RB	O
used	use	VBN	O
for	for	IN	O
sulphonamides	sulphonamide	NNS	O
inhibitors	inhibitor	NNS	O
.	.	.	O

It	-PRON-	PRP	O
was	be	VBD	O
previously	previously	RB	O
shown	show	VBN	O
that	that	IN	O
phosphonamidates	phosphonamidate	NNS	O
possess	possess	VBP	O
a	a	DT	O
significantly	significantly	RB	O
lower	low	JJR	O
acidity	acidity	NN	O
more	more	JJR	O
than	than	IN	O
2	2	CD	O
orders	order	NNS	O
of	of	IN	O
magnitude	magnitude	NN	O
than	than	IN	O
the	the	DT	O
bioisosteres	bioisostere	NNS	O
sulphonamides	sulphonamide	NNS	O
which	which	WDT	O
presumably	presumably	RB	O
induce	induce	VBP	O
an	an	DT	O
extended	extended	JJ	O
time	time	NN	O
needed	need	VBN	O
to	to	TO	O
form	form	VB	O
the	the	DT	O
EâI	EâI	NNP	O
complex	complex	NN	O
.	.	.	O

The	the	DT	O
inhibition	inhibition	NN	O
profiles	profile	VBZ	O
against	against	IN	O
the	the	DT	O
human	human	JJ	O
ubiquitous	ubiquitous	JJ	O
CAs	ca	NNS	O
I	-PRON-	PRP	O
and	and	CC	O
II	II	NNP	O
are	be	VBP	O
displayed	display	VBN	O
for	for	IN	O
comparison	comparison	NN	O
.	.	.	O

The	the	DT	O
following	following	JJ	O
structureâactivity	structureâactivity	NN	O
relationships	relationship	NNS	O
SAR	SAR	NNP	O
can	can	MD	O
be	be	VB	O
assembled	assemble	VBN	O
from	from	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
data	datum	NNS	O
reported	report	VBN	O
in	in	IN	O
Table	table	NN	O
1	1	CD	O
.	.	.	O

Inhibition	inhibition	NN	O
data	datum	NNS	O
of	of	IN	O
VChÎ²	VChÎ²	NNP	O
,	,	,	O
FtuÎ²CA	FtuÎ²CA	NNP	O
,	,	,	O
BpsCAÎ²	BpsCAÎ²	NNP	O
,	,	,	O
Can2	Can2	NNP	O
,	,	,	O
CgNce	CgNce	NNP	O
,	,	,	O
MgCA	MgCA	NNP	O
and	and	CC	O
LdcCA	LdcCA	NNP	O
with	with	IN	O
phenylphosphonic	phenylphosphonic	JJ	O
diamide	diamide	NN	O
2	2	CD	O
and	and	CC	O
alkyl	alkyl	NN	O
phosphonamidates	phosphonamidate	VBZ	O
3â10	3â10	CD	O
and	and	CC	O
the	the	DT	O
standard	standard	JJ	O
sulphonamide	sulphonamide	JJ	O
inhibitor	inhibitor	NN	O
acetazolamide	acetazolamide	NN	O
AAZ	AAZ	NNP	O
by	by	IN	O
a	a	DT	O
stopped	stop	VBN	O
flow	flow	NN	O
CO2	CO2	NNP	O
hydrase	hydrase	NN	O
assay	assay	NN	B
.	.	.	O

Mean	mean	VB	O
from	from	IN	O
three	three	CD	O
different	different	JJ	O
assays	assay	NNS	O
,	,	,	O
by	by	IN	O
a	a	DT	O
stopped	stop	VBN	O
flow	flow	NN	O
technique	technique	NN	O
errors	error	NNS	O
were	be	VBD	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
of	of	IN	O
Â±5â10	â±5â10	CC	O
%	%	NN	O
of	of	IN	O
the	the	DT	O
reported	report	VBN	O
values	value	NNS	O
.	.	.	O

What	what	WP	O
immediately	immediately	RB	O
stands	stand	VBZ	O
out	out	RP	O
from	from	IN	O
the	the	DT	O
data	datum	NNS	O
in	in	IN	O
Table	table	NN	O
1	1	CD	O
is	be	VBZ	O
that	that	IN	O
benzenephosphonamidates	benzenephosphonamidates	NNP	O
2â10	2â10	CD	O
act	act	NN	O
as	as	IN	O
significantly	significantly	RB	O
stronger	strong	JJR	O
inhibitors	inhibitor	NNS	O
against	against	IN	O
the	the	DT	O
tested	test	VBN	O
Î²-class	î²-class	CD	O
CAs	ca	NNS	O
than	than	IN	O
CA	CA	NNP	O
I	I	NNP	O
and	and	CC	O
CA	CA	NNP	O
II	II	NNP	O
.	.	.	O

In	in	IN	O
fact	fact	NN	O
,	,	,	O
low	low	JJ	O
to	to	IN	O
submicromolar	submicromolar	JJ	O
inhibition	inhibition	NN	O
constants	constant	NNS	O
KIs	KIs	NNP	O
were	be	VBD	O
measured	measure	VBN	O
against	against	IN	O
VChÎ²	vchî²	ADD	O
KIsâ=â0.5â64.9âÂµM	KIsâ=â0.5â64.9âÂµM	,	O
,	,	,	O
FtuÎ²CA	FtuÎ²CA	NNP	O
KIsâ=â6.9â55.3âÂµM	kisâ=â6.9â55.3ââµm	NN	O
,	,	,	O
BpsCAÎ²	BpsCAÎ²	NNP	O
KIsâ=â2.1â32.7âÂµM	KIsâ=â2.1â32.7âÂµM	NNP	O
,	,	,	O
Can2	Can2	NNP	O
KIsâ=â0.02â10.4âÂµM	KIsâ=â0.02â10.4âÂµM	NNP	O
,	,	,	O
CgNce	CgNce	NNP	O
KIsâ=â0.05â20.2âÂµM	KIsâ=â0.05â20.2âÂµM	NNP	O
,	,	,	O
and	and	CC	O
LdcCA	LdcCA	NNP	O
KIsâ=â0.8â36.5âÂµM	KIsâ=â0.8â36.5âÂµM	NNP	O
,	,	,	O
whereas	whereas	IN	O
solely	solely	RB	O
MgCA	MgCA	NNP	O
was	be	VBD	O
inhibited	inhibit	VBN	O
in	in	IN	O
a	a	DT	O
medium	medium	JJ	O
micromolar	micromolar	JJ	O
range	range	NN	O
KIsâ=â26.1â265.7âÂµM	KIsâ=â26.1â265.7âÂµM	NNP	O
.	.	.	O

In	in	IN	O
contrast	contrast	NN	O
,	,	,	O
CAs	CAs	NNP	O
I	I	NNP	O
and	and	CC	O
II	II	NNP	O
had	have	VBD	O
been	be	VBN	O
shown	show	VBN	O
to	to	TO	O
be	be	VB	O
target	target	NN	O
of	of	IN	O
compounds	compound	NNS	O
2â10	2â10	CD	O
in	in	IN	O
a	a	DT	O
medium	medium	NN	O
to	to	IN	O
high	high	JJ	O
micromolar	micromolar	JJ	O
scale	scale	NN	O
spanning	span	VBG	O
from	from	IN	O
77.8	77.8	CD	O
to	to	IN	O
961.2âÂµM	961.2ââµm	CD	O
and	and	CC	O
32.8	32.8	CD	O
to	to	IN	O
520.1âÂµM	520.1ââµm	CD	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

Using	use	VBG	O
in	in	IN	O
silico	silico	NN	O
techniques	technique	NNS	O
,	,	,	O
phosphonamidates	phosphonamidate	NNS	O
have	have	VBP	O
been	be	VBN	O
reported	report	VBN	O
to	to	TO	O
act	act	VB	O
as	as	IN	O
zinc	zinc	NN	O
-	-	HYPH	O
binding	bind	VBG	O
group	group	NN	O
in	in	IN	O
the	the	DT	O
interaction	interaction	NN	O
with	with	IN	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
of	of	IN	O
hCA	hca	CD	O
II	II	NNP	O
Figure	Figure	NNP	O
1	1	CD	O
and	and	CC	O
thus	thus	RB	O
it	-PRON-	PRP	O
is	be	VBZ	O
not	not	RB	O
unexpected	unexpected	JJ	O
that	that	IN	O
the	the	DT	O
incorporation	incorporation	NN	O
of	of	IN	O
gradually	gradually	RB	O
bulkier	bulky	JJR	O
substituents	substituent	NNS	O
on	on	IN	O
the	the	DT	O
phosphorus	phosphorus	NN	O
atom	atom	NN	O
might	may	MD	O
decrease	decrease	VB	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
effectiveness	effectiveness	NN	O
of	of	IN	O
this	this	DT	O
class	class	NN	O
of	of	IN	O
compounds	compound	NNS	O
because	because	IN	O
of	of	IN	O
steric	steric	JJ	O
hindrance	hindrance	NN	O
induced	induce	VBN	O
nearby	nearby	RB	O
the	the	DT	O
zinc	zinc	NN	O
ion	ion	NN	O
.	.	.	O

Nonetheless	nonetheless	RB	O
,	,	,	O
the	the	DT	O
reduction	reduction	NN	O
of	of	IN	O
inhibition	inhibition	NN	O
potency	potency	NN	O
against	against	IN	O
Î²-class	Î²-class	NNP	O
CAs	ca	NNS	O
upon	upon	IN	O
increasing	increase	VBG	O
the	the	DT	O
length	length	NN	O
of	of	IN	O
the	the	DT	O
alkyl	alkyl	NN	O
chain	chain	NN	O
was	be	VBD	O
not	not	RB	O
as	as	RB	O
significant	significant	JJ	O
as	as	IN	O
that	that	DT	O
reported	report	VBD	O
against	against	IN	O
hCAs	hcas	PRP	O
,	,	,	O
and	and	CC	O
thus	thus	RB	O
other	other	JJ	O
binding	bind	VBG	O
factors	factor	NNS	O
appear	appear	VBP	O
to	to	TO	O
take	take	VB	O
place	place	NN	O
within	within	IN	O
the	the	DT	O
binding	bind	VBG	O
site	site	NN	O
of	of	IN	O
Î²-CAs	Î²-CAs	NNP	O
.	.	.	O

In	in	IN	O
detail	detail	NN	O
,	,	,	O
phenylphosphonic	phenylphosphonic	NN	O
diamide	diamide	NN	O
2	2	CD	O
and	and	CC	O
methyl	methyl	NN	O
phosphonamidate	phosphonamidate	NN	O
3	3	CD	O
indistinctly	indistinctly	RB	O
showed	show	VBD	O
the	the	DT	O
best	good	JJS	O
inhibitory	inhibitory	JJ	O
potency	potency	NN	O
against	against	IN	O
VChÎ²	VChÎ²	NNP	O
KIs	ki	NNS	O
of	of	IN	O
0.9	0.9	CD	O
and	and	CC	O
0.5âÂµM	0.5âÂµM	NNP	O
,	,	,	O
BpsCAÎ²	BpsCAÎ²	NNP	O
KIs	KIs	NNP	O
of	of	IN	O
2.5	2.5	CD	O
and	and	CC	O
2.1âÂµM	2.1ââµm	CD	O
,	,	,	O
Can2	Can2	NNP	O
KIs	ki	NNS	O
of	of	IN	O
0.03	0.03	CD	O
and	and	CC	O
0.02âÂµM	0.02âÂµM	NNP	O
,	,	,	O
CgNce	CgNce	NNP	O
KIs	ki	NNS	O
of	of	IN	O
0.05	0.05	CD	O
and	and	CC	O
0.2âÂµM	0.2âÂµM	NNP	O
,	,	,	O
MgCA	MgCA	NNP	O
KIs	ki	NNS	O
of	of	IN	O
28.4	28.4	CD	O
and	and	CC	O
26.1âÂµM	26.1ââµm	CD	O
,	,	,	O
and	and	CC	O
LdcCA	LdcCA	NNP	O
KIs	ki	NNS	O
of	of	IN	O
2.1	2.1	CD	O
and	and	CC	O
0.8âÂµM	0.8âÂµM	NNP	O
among	among	IN	O
the	the	DT	O
reported	report	VBN	O
compounds	compound	NNS	O
.	.	.	O

As	as	IN	O
a	a	DT	O
unique	unique	JJ	O
exception	exception	NN	O
,	,	,	O
FtuÎ²CA	FtuÎ²CA	NNP	O
was	be	VBD	O
found	find	VBN	O
to	to	TO	O
be	be	VB	O
most	most	RBS	O
potently	potently	RB	O
inhibited	inhibit	VBN	O
by	by	IN	O
the	the	DT	O
propargyl	propargyl	NN	O
phosphonamidate	phosphonamidate	NN	O
10	10	CD	O
which	which	WDT	O
shows	show	VBZ	O
a	a	DT	O
KI	KI	NNP	O
of	of	IN	O
6.9âÂµM.	6.9âÂµM.	NNP	O
In	in	IN	O
the	the	DT	O
cases	case	NNS	O
of	of	IN	O
BpsCAÎ²	BpsCAÎ²	NNP	O
and	and	CC	O
Can2	Can2	NNP	O
,	,	,	O
the	the	DT	O
ethyl	ethyl	NN	O
derivative	derivative	NN	O
4	4	CD	O
showed	show	VBD	O
a	a	DT	O
comparable	comparable	JJ	O
inhibition	inhibition	NN	O
to	to	IN	O
compounds	compound	NNS	O
2	2	CD	O
and	and	CC	O
3	3	CD	O
,	,	,	O
with	with	IN	O
KIs	ki	NNS	O
of	of	IN	O
4.6	4.6	CD	O
and	and	CC	O
0.05âÂµM	0.05âÂµM	NNP	O
,	,	,	O
and	and	CC	O
further	further	RB	O
showed	show	VBD	O
an	an	DT	O
interesting	interesting	JJ	O
submicromolar	submicromolar	JJ	O
KI	KI	NNP	O
of	of	IN	O
0.8âÂµM	0.8âÂµM	NNP	O
against	against	IN	O
CgNce	CgNce	NNP	O
.	.	.	O

Branching	branch	VBG	O
of	of	IN	O
the	the	DT	O
alkyl	alkyl	NN	O
chain	chain	NN	O
from	from	IN	O
propyl	propyl	NNP	O
5	5	CD	O
to	to	TO	O
isopropyl	isopropyl	VB	O
6	6	CD	O
always	always	RB	O
produced	produce	VBD	O
a	a	DT	O
positive	positive	JJ	O
effect	effect	NN	O
on	on	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
potency	potency	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
two	two	CD	O
-	-	HYPH	O
fold	fold	RB	O
against	against	IN	O
VChÎ²	VChÎ²	NNP	O
,	,	,	O
FtuÎ²CA	FtuÎ²CA	NNP	O
,	,	,	O
BpsCAÎ²	BpsCAÎ²	NNP	O
,	,	,	O
and	and	CC	O
CgNce	CgNce	NNP	O
and	and	CC	O
nine	nine	CD	O
-	-	HYPH	O
fold	fold	RB	O
against	against	IN	O
Can2	Can2	NNP	O
KI	KI	NNP	O
from	from	IN	O
0.9	0.9	CD	O
to	to	IN	O
0.1âÂµM	0.1ââµm	CD	O
.	.	.	O

Switching	switch	VBG	O
the	the	DT	O
propyl	propyl	NN	O
6	6	CD	O
to	to	IN	O
a	a	DT	O
propargyl	propargyl	NN	O
10	10	CD	O
produced	produce	VBN	O
instead	instead	RB	O
a	a	DT	O
positive	positive	JJ	O
effect	effect	NN	O
uniquely	uniquely	RB	O
in	in	IN	O
the	the	DT	O
case	case	NN	O
of	of	IN	O
FtuÎ²CA	FtuÎ²CA	NNP	O
KI	KI	NNP	O
from	from	IN	O
35.6	35.6	CD	O
to	to	IN	O
6.9âÂµM	6.9ââµm	CD	O
.	.	.	O

Enhancement	enhancement	NN	O
of	of	IN	O
inhibitory	inhibitory	JJ	O
potency	potency	NN	O
against	against	IN	O
FtuÎ²CA	FtuÎ²CA	NNP	O
KI	KI	NNP	O
from	from	IN	O
35.6	35.6	CD	O
to	to	IN	O
15.1âÂµM	15.1ââµm	CD	O
and	and	CC	O
Can2	Can2	NNP	O
KI	KI	NNP	O
from	from	IN	O
0.9	0.9	CD	O
to	to	IN	O
0.6âÂµM	0.6ââµm	CD	O
is	be	VBZ	O
also	also	RB	O
provoked	provoke	VBN	O
by	by	IN	O
swapping	swap	VBG	O
the	the	DT	O
terminal	terminal	JJ	O
CH3	CH3	NNP	O
of	of	IN	O
the	the	DT	O
propyl	propyl	NN	O
of	of	IN	O
5	5	CD	O
with	with	IN	O
a	a	DT	O
chlorine	chlorine	NN	O
atom	atom	NN	O
as	as	IN	O
in	in	IN	O
9	9	CD	O
,	,	,	O
whereas	whereas	IN	O
the	the	DT	O
two	two	CD	O
compounds	compound	NNS	O
inhibit	inhibit	VBP	O
CgNce	CgNce	NNP	O
almost	almost	RB	O
equally	equally	RB	O
KIs	ki	NNS	O
of	of	IN	O
1.3	1.3	CD	O
and	and	CC	O
1.8âÂµM	1.8ââµm	CD	O
.	.	.	O

The	the	DT	O
standard	standard	JJ	O
AAZ	AAZ	NNP	O
is	be	VBZ	O
a	a	DT	O
more	more	RBR	O
effective	effective	JJ	O
inhibitor	inhibitor	NN	O
of	of	IN	O
all	all	DT	O
tested	test	VBN	O
Î²-CAs	Î²-CAs	NNP	O
than	than	IN	O
phosphonamidates	phosphonamidate	NNS	O
2â10	2â10	CD	O
here	here	RB	O
investigated	investigate	VBN	O
KIs	ki	NNS	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
0.01â0.77âÂµM	0.01â0.77âÂµM	NNP	O
,	,	,	O
with	with	IN	O
the	the	DT	O
exception	exception	NN	O
of	of	IN	O
MgCA	MgCA	NNP	O
,	,	,	O
against	against	IN	O
which	which	WDT	O
it	-PRON-	PRP	O
showed	show	VBD	O
a	a	DT	O
KI	KI	NNP	O
of	of	IN	O
40âÂµM	40ââµm	CD	O
,	,	,	O
whereas	whereas	IN	O
the	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
compounds	compound	NNS	O
2	2	CD	O
and	and	CC	O
3	3	CD	O
act	act	NN	O
with	with	IN	O
KIs	ki	NNS	O
of	of	IN	O
28.4	28.4	CD	O
and	and	CC	O
26.1âÂµM.	26.1âÂµM.	NNP	O
However	however	RB	O
,	,	,	O
AAZ	AAZ	NNP	O
also	also	RB	O
inhibits	inhibit	VBZ	O
CA	CA	NNP	O
I	I	NNP	O
and	and	CC	O
II	ii	CD	O
in	in	IN	O
a	a	DT	O
medium	medium	NN	O
to	to	IN	O
low	low	JJ	O
nanomolar	nanomolar	JJ	O
range	range	NN	O
,	,	,	O
while	while	IN	O
KIs	ki	NNS	O
of	of	IN	O
compounds	compound	NNS	O
2â10	2â10	CD	O
do	do	VBP	O
not	not	RB	O
go	go	VB	O
below	below	IN	O
30âÂµM	30ââµm	CD	O
against	against	IN	O
these	these	DT	O
human	human	JJ	O
isozymes	isozyme	NNS	O
.	.	.	O

In	in	IN	O
Table	table	NN	O
2	2	CD	O
,	,	,	O
the	the	DT	O
selectivity	selectivity	NN	O
index	index	NN	O
SI	SI	NNP	O
for	for	IN	O
the	the	DT	O
target	target	NN	O
Î²-CAs	î²-ca	VBN	O
over	over	IN	O
hCA	hca	CD	O
II	II	NNP	O
is	be	VBZ	O
reported	report	VBN	O
.	.	.	O

With	with	IN	O
the	the	DT	O
exception	exception	NN	O
of	of	IN	O
MgCA	MgCA	NNP	O
,	,	,	O
all	all	DT	O
tested	test	VBN	O
phosphonamidates	phosphonamidate	NNS	O
show	show	VBP	O
a	a	DT	O
remarkably	remarkably	RB	O
selective	selective	JJ	O
inhibitory	inhibitory	JJ	O
action	action	NN	O
against	against	IN	O
all	all	DT	O
Î²-CAs	Î²-CAs	NNP	O
over	over	IN	O
the	the	DT	O
most	most	RBS	O
relevant	relevant	JJ	O
human	human	JJ	O
isozyme	isozyme	NNS	O
.	.	.	O

While	while	IN	O
the	the	DT	O
SI	SI	NNP	O
for	for	IN	O
VChÎ²	VChÎ²	NNP	O
,	,	,	O
FtuÎ²CA	FtuÎ²CA	NNS	O
,	,	,	O
LdcCA	LdcCA	NNP	O
and	and	CC	O
BpsCAÎ²	BpsCAÎ²	NNP	O
over	over	IN	O
hCA	hCA	NNP	O
II	II	NNP	O
span	span	NN	O
between	between	IN	O
2.7	2.7	CD	O
and	and	CC	O
79.6	79.6	CD	O
,	,	,	O
it	-PRON-	PRP	O
is	be	VBZ	O
noteworthy	noteworthy	JJ	O
stressing	stress	VBG	O
the	the	DT	O
up	up	IN	O
to	to	TO	O
four	four	CD	O
-	-	HYPH	O
digits	digit	VBG	O
SI	SI	NNP	O
calculated	calculate	VBN	O
for	for	IN	O
a	a	DT	O
subset	subset	NN	O
of	of	IN	O
compounds	compound	NNS	O
against	against	IN	O
Can2	Can2	NNP	O
1093.3â3488.0	1093.3â3488.0	CD	O
and	and	CC	O
the	the	DT	O
three	three	CD	O
-	-	HYPH	O
digits	digit	VBG	O
SI	SI	NNP	O
that	that	WDT	O
compounds	compound	VBZ	O
2â7	2â7	CD	O
showed	show	VBD	O
against	against	IN	O
CgNce	CgNce	NNP	O
141.5â656.0	141.5â656.0	CD	O
.	.	.	O

Selectivity	Selectivity	NNP	O
index	index	NN	O
SI	SI	NNP	O
for	for	IN	O
target	target	NN	O
Î²-CAs	Î²-CAs	NNP	O
over	over	IN	O
hCA	hca	CD	O
II	II	NNP	O
.	.	.	O

AAZ	AAZ	NNP	O
weakly	weakly	WDT	O
inhibits	inhibit	VBZ	O
MgCA	MgCA	NNP	O
from	from	IN	O
M.	M.	NNP	O
globosa	globosa	NNP	O
whereas	whereas	IN	O
phosphonamidates	phosphonamidate	VBZ	O
2â10	2â10	CD	O
inhibit	inhibit	NN	O
this	this	DT	O
enzyme	enzyme	NNS	O
less	less	RBR	O
effectively	effectively	RB	O
than	than	IN	O
other	other	JJ	O
screened	screen	VBN	O
Î²-CAs	Î²-CAs	NNP	O
and	and	CC	O
almost	almost	RB	O
comparably	comparably	RB	O
with	with	IN	O
hCA	hca	CD	O
II	ii	CD	O
,	,	,	O
leading	lead	VBG	O
to	to	IN	O
SI	SI	NNP	O
ranging	range	VBG	O
between	between	IN	O
0.8	0.8	CD	O
and	and	CC	O
7.3	7.3	CD	O
.	.	.	O

Selectivity	selectivity	NN	O
indexes	index	NNS	O
for	for	IN	O
the	the	DT	O
target	target	NN	O
Î²-CA	Î²-CA	-LRB-	O
over	over	IN	O
hCA	hCA	NNP	O
I	-PRON-	PRP	O
are	be	VBP	O
obviously	obviously	RB	O
even	even	RB	O
higher	high	JJR	O
than	than	IN	O
those	those	DT	O
depicted	depict	VBN	O
in	in	IN	O
Table	Table	NNP	O
2	2	CD	O
because	because	IN	O
hCA	hca	XX	O
I	-PRON-	PRP	O
is	be	VBZ	O
less	less	RBR	O
inhibited	inhibited	JJ	O
than	than	IN	O
hCA	hCA	NNP	O
II	II	NNP	O
by	by	IN	O
derivatives	derivative	NNS	O
2â10	2â10	CD	O
.	.	.	O

Significantly	significantly	RB	O
higher	high	JJR	O
SI	SI	NNP	O
have	have	VBP	O
been	be	VBN	O
calculated	calculate	VBN	O
with	with	IN	O
most	most	JJS	O
phosphonamidates	phosphonamidate	NNS	O
for	for	IN	O
Î²-class	î²-clas	NNS	O
CAs	ca	NNS	O
over	over	IN	O
human	human	JJ	O
isoform	isoform	NN	O
II	II	NNP	O
in	in	IN	O
comparison	comparison	NN	O
to	to	TO	O
sulphonamide	sulphonamide	VB	O
derivatives	derivative	NNS	B
,	,	,	O
which	which	WDT	O
are	be	VBP	O
here	here	RB	O
represented	represent	VBN	O
by	by	IN	O
AAZ	AAZ	NNP	O
SI	SI	NNP	O
in	in	IN	O
the	the	DT	O
range	range	NN	O
<	<	XX	O
0.01â1.0	0.01â1.0	NNP	O
,	,	,	O
Table	table	NN	O
2	2	CD	O
.	.	.	O

These	these	DT	O
data	datum	NNS	O
include	include	VBP	O
this	this	DT	O
new	new	JJ	O
class	class	NN	O
of	of	IN	O
compounds	compound	NNS	O
among	among	IN	O
the	the	DT	O
CAIs	CAIs	NNPS	O
most	most	RBS	O
selective	selective	JJ	O
for	for	IN	O
Î²-class	î²-class	NN	O
over	over	RP	O
human	human	JJ	O
isozymes	isozyme	NNS	O
known	know	VBN	O
to	to	IN	O
date	date	NN	O
.	.	.	O

One	one	PRP	O
could	could	MD	O
speculate	speculate	VB	O
that	that	IN	O
the	the	DT	O
narrower	narrower	RBR	O
active	active	JJ	O
site	site	NN	O
pocket	pocket	NN	O
of	of	IN	O
Î²-CAs	Î²-CAs	NNP	O
better	well	RBR	O
accommodates	accommodates	JJ	O
benzenephosphonamidates	benzenephosphonamidate	NNS	O
than	than	IN	O
the	the	DT	O
roomier	roomier	NN	O
binding	bind	VBG	O
cavity	cavity	NN	O
of	of	IN	O
human	human	JJ	O
CAs	ca	NNS	O
in	in	IN	O
terms	term	NNS	O
of	of	IN	O
binding	bind	VBG	O
interactions	interaction	NNS	O
.	.	.	O

Indeed	indeed	RB	O
,	,	,	O
a	a	DT	O
recent	recent	JJ	O
paper	paper	NN	O
by	by	IN	O
us	-PRON-	PRP	O
showed	show	VBD	O
that	that	IN	O
the	the	DT	O
binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
benzoxaboroles	benzoxaborole	NNS	O
within	within	IN	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
of	of	IN	O
Î²-CAs	Î²-CAs	NNP	O
Can2	Can2	NNP	O
and	and	CC	O
MgCA	MgCA	NNP	O
is	be	VBZ	O
strongly	strongly	RB	O
driven	drive	VBN	O
by	by	IN	O
ÏâÏ	ïâï	CD	O
interactions	interaction	NNS	O
involving	involve	VBG	O
aromatic	aromatic	JJ	O
residues	residue	NNS	O
solely	solely	RB	O
present	present	JJ	O
in	in	IN	O
Î²-class	î²-class	JJ	O
enzymes	enzyme	NNS	B
.	.	.	O

Analogue	analogue	NN	O
binding	bind	VBG	O
interactions	interaction	NNS	O
might	may	MD	O
exist	exist	VB	O
with	with	IN	O
benzenephosphonamidates	benzenephosphonamidate	NNS	O
,	,	,	O
which	which	WDT	O
increase	increase	VBP	O
their	-PRON-	PRP$	O
inhibition	inhibition	NN	O
effectiveness	effectiveness	NN	O
against	against	IN	O
Î²-CAs	Î²-CAs	NNP	O
.	.	.	O

Novel	novel	JJ	O
insights	insight	NNS	O
are	be	VBP	O
emerging	emerge	VBG	O
by	by	IN	O
novel	novel	JJ	O
crystallographic	crystallographic	JJ	O
studies	study	NNS	O
currently	currently	RB	O
ongoing	ongoing	JJ	O
with	with	IN	O
phosphonamidates	phosphonamidate	NNS	O
and	and	CC	O
hCAs	hcas	NN	O
,	,	,	O
which	which	WDT	O
will	will	MD	O
definitively	definitively	RB	O
clarify	clarify	VB	O
the	the	DT	O
binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
such	such	PDT	O
a	a	DT	O
chemotype	chemotype	NN	O
with	with	IN	O
these	these	DT	O
metalloenzymes	metalloenzyme	NNS	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
this	this	DT	O
knowledge	knowledge	NN	O
will	will	MD	O
be	be	VB	O
extended	extend	VBN	O
to	to	TO	O
visualise	visualise	VB	O
the	the	DT	O
reasons	reason	NNS	O
for	for	IN	O
benzenephosphonamidates	benzenephosphonamidate	NNS	O
selective	selective	JJ	O
action	action	NN	O
against	against	IN	O
Î²-	î²-	NN	O
over	over	IN	O
Î±-class	î±-class	NN	O
enzymes	enzyme	NNS	O
.	.	.	O

The	the	DT	O
robust	robust	JJ	O
spread	spread	NN	O
of	of	IN	O
antimicrobial	antimicrobial	JJ	O
resistance	resistance	NN	O
represents	represent	VBZ	O
a	a	DT	O
main	main	JJ	O
threat	threat	NN	O
to	to	IN	O
human	human	JJ	O
health	health	NN	O
.	.	.	O

A	a	DT	O
primary	primary	JJ	O
strategy	strategy	NN	O
to	to	TO	O
combat	combat	VB	O
it	-PRON-	PRP	O
consists	consist	VBZ	O
in	in	IN	O
the	the	DT	O
identification	identification	NN	O
of	of	IN	O
novel	novel	JJ	O
therapeutic	therapeutic	JJ	O
targets	target	NNS	O
and	and	CC	O
anti	anti	NNS	O
-	-	NN	O
infectives	infective	NNS	O
with	with	IN	O
alternative	alternative	JJ	O
mechanisms	mechanism	NNS	O
of	of	IN	O
action	action	NN	O
.	.	.	O

The	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
the	the	DT	O
metalloenzymes	metalloenzymes	NNP	O
carbonic	carbonic	NNP	O
anhydrases	anhydrase	NNS	O
CAs	CAs	NNP	O
,	,	,	O
EC	EC	NNP	O
4.2.1.1	4.2.1.1	CD	O
from	from	IN	O
pathogens	pathogen	NNS	O
among	among	IN	O
bacteria	bacteria	NNS	O
,	,	,	O
fungi	fungi	NN	O
,	,	,	O
and	and	CC	O
protozoa	protozoa	NN	O
was	be	VBD	O
shown	show	VBN	O
to	to	TO	O
produce	produce	VB	O
an	an	DT	O
impairment	impairment	NN	O
of	of	IN	O
the	the	DT	O
microorganism	microorganism	NN	O
growth	growth	NN	O
and	and	CC	O
virulence	virulence	NN	O
,	,	,	O
whose	whose	WP$	O
targeting	targeting	NN	O
is	be	VBZ	O
deemed	deem	VBN	O
to	to	TO	O
prevent	prevent	VB	O
the	the	DT	O
evolutionary	evolutionary	JJ	O
selective	selective	JJ	O
pressures	pressure	NNS	O
that	that	WDT	O
induce	induce	VBP	O
the	the	DT	O
pathogen	pathogen	NN	O
to	to	TO	O
develop	develop	VB	O
resistance	resistance	NN	O
.	.	.	O

Unlike	unlike	IN	O
mammals	mammal	NNS	O
and	and	CC	O
thus	thus	RB	O
human	human	JJ	O
,	,	,	O
the	the	DT	O
genome	genome	NN	O
of	of	IN	O
many	many	JJ	O
pathogenic	pathogenic	JJ	O
bacteria	bacteria	NNS	O
,	,	,	O
fungi	fungi	NN	O
,	,	,	O
and	and	CC	O
protozoa	protozoa	JJ	O
encode	encode	NN	O
for	for	IN	O
Î²-class	î²-class	JJ	O
enzymes	enzyme	NNS	O
,	,	,	O
which	which	WDT	O
show	show	VBP	O
significant	significant	JJ	O
structural	structural	JJ	O
diversities	diversity	NNS	O
compared	compare	VBN	O
to	to	IN	O
Î±-class	î±-class	NN	O
isozymes	isozyme	NNS	O
.	.	.	O

As	as	IN	O
phosphonamidates	phosphonamidate	NNS	O
have	have	VBP	O
been	be	VBN	O
recently	recently	RB	O
validated	validate	VBN	O
as	as	IN	O
human	human	JJ	O
Î±-CA	Î±-CA	NNP	O
inhibitors	inhibitor	NNS	O
CAIs	CAIs	NNP	O
and	and	CC	O
no	no	DT	O
phosphorus	phosphorus	NN	O
-	-	HYPH	O
based	base	VBN	O
zinc	zinc	NN	O
-	-	HYPH	O
binding	bind	VBG	O
group	group	NN	O
have	have	VBP	O
been	be	VBN	O
assessed	assess	VBN	O
to	to	IN	O
date	date	NN	O
against	against	IN	O
Î²-class	Î²-class	NNP	O
CAs	CAs	NNP	O
,	,	,	O
herein	herein	NNP	O
we	-PRON-	PRP	O
report	report	VBP	O
an	an	DT	O
inhibition	inhibition	NN	O
study	study	NN	O
with	with	IN	O
this	this	DT	O
class	class	NN	O
of	of	IN	O
compounds	compound	NNS	O
against	against	IN	O
Î²-CAs	Î²-CAs	NNP	O
from	from	IN	O
pathogenic	pathogenic	JJ	O
bacteria	bacteria	NNS	O
,	,	,	O
fungi	fungi	NN	O
,	,	,	O
and	and	CC	O
protozoa	protozoa	NN	O
.	.	.	O

Compounds	compound	NNS	O
2â10	2â10	CD	O
showed	show	VBD	O
low	low	JJ	O
to	to	IN	O
submicromolar	submicromolar	JJ	O
KIs	ki	NNS	O
against	against	IN	O
most	most	RBS	O
tested	test	VBN	O
Î²-CAs	Î²-CAs	NNP	O
,	,	,	O
namely	namely	RB	O
VChÎ²	vchî²	ADD	O
KIsâ=â0.5â64.9âÂµM	KIsâ=â0.5â64.9âÂµM	,	O
,	,	,	O
FtuÎ²CA	FtuÎ²CA	NNP	O
KIsâ=â6.9â55.3âÂµM	kisâ=â6.9â55.3ââµm	NN	O
,	,	,	O
BpsCAÎ²	BpsCAÎ²	NNP	O
KIsâ=â2.1â32.7âÂµM	KIsâ=â2.1â32.7âÂµM	NNP	O
,	,	,	O
Can2	Can2	NNP	O
KIsâ=â0.02â10.4âÂµM	KIsâ=â0.02â10.4âÂµM	NNP	O
,	,	,	O
CgNce	CgNce	NNP	O
KIsâ=â0.05â20.2âÂµM	KIsâ=â0.05â20.2âÂµM	NNP	O
,	,	,	O
and	and	CC	O
LdcCA	LdcCA	NNP	O
KIsâ=â0.8â36.5âÂµM	KIsâ=â0.8â36.5âÂµM	NNP	O
.	.	.	O

As	as	IN	O
human	human	JJ	O
isoforms	isoform	NNS	O
CAs	CAs	NNP	O
I	I	NNP	O
and	and	CC	O
II	II	NNP	O
are	be	VBP	O
instead	instead	RB	O
solely	solely	RB	O
inhibited	inhibit	VBN	O
in	in	IN	O
a	a	DT	O
high	high	JJ	O
micromolar	micromolar	JJ	O
range	range	NN	O
32.8â961.2âÂµM	32.8â961.2ââµm	CD	O
,	,	,	O
these	these	DT	O
data	datum	NNS	O
include	include	VBP	O
phosphonamidates	phosphonamidate	NNS	O
among	among	IN	O
the	the	DT	O
CAIs	CAIs	NNPS	O
most	most	RBS	O
selective	selective	JJ	O
for	for	IN	O
Î²-class	î²-class	NN	O
over	over	RP	O
human	human	JJ	O
isozymes	isozyme	NNS	O
known	know	VBN	O
to	to	IN	O
date	date	NN	O
,	,	,	O
making	make	VBG	O
them	-PRON-	PRP	O
interesting	interesting	JJ	O
leads	lead	NNS	O
for	for	IN	O
the	the	DT	O
development	development	NN	O
of	of	IN	O
new	new	JJ	O
anti	anti	JJ	O
-	-	JJ	O
infective	infective	JJ	O
agents	agent	NNS	O
.	.	.	O

Crystallographic	crystallographic	JJ	O
studies	study	NNS	O
currently	currently	RB	O
ongoing	ongoing	JJ	O
with	with	IN	O
phosphonamidates	phosphonamidate	NNS	O
2â10	2â10	CD	O
and	and	CC	O
hCAs	hcas	NN	O
will	will	MD	O
definitively	definitively	RB	O
clarify	clarify	VB	O
the	the	DT	O
mechanism	mechanism	NN	O
of	of	IN	O
action	action	NN	O
of	of	IN	O
this	this	DT	O
class	class	NN	O
of	of	IN	O
compounds	compound	NNS	O
probably	probably	RB	O
shedding	shed	VBG	O
light	light	NN	O
on	on	IN	O
their	-PRON-	PRP$	O
selective	selective	JJ	O
efficacy	efficacy	NN	O
against	against	IN	O
Î²-	î²-	NN	O
over	over	IN	O
Î±-class	î±-class	NN	O
enzymes	enzyme	NNS	O
